1 / 15

Long term anti-psychotic treatment in schizophrenia:  30 years of data and experience

Long term anti-psychotic treatment in schizophrenia:  30 years of data and experience. Nina R. Schooler, Ph.D. Georgetown University School of Medicine VISN 5 MIRECC Department of Veterans Affairs. Overview. Prevention of relapse

libitha
Download Presentation

Long term anti-psychotic treatment in schizophrenia:  30 years of data and experience

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Long term anti-psychotic treatment in schizophrenia: 30 years of data and experience Nina R. Schooler, Ph.D. Georgetown University School of Medicine VISN 5 MIRECC Department of Veterans Affairs

  2. Overview • Prevention of relapse • Need long term trials targeting symptomatically stable patients • Placebo produces: • High relapse and rehospitalization for patients in the community • High symptom exacerbation for hospitalized patients • Can placebo controlled trials be conducted without these consequences? • Rescue medications are ineffective

  3. 1970’s Placebo Controlled Relapse Prevention TrialStudy Design • Schizophrenia diagnosis • Community dwelling stabilized patients • 2 year treatment period • 2 X 2 Design • Chlorpromazine v PBO • Psychosocial treatment v treatment as usual • Definition of relapse required return of psychotic symptoms • Multi center US • sponsored by NIMH Hogarty et al 1974

  4. 1970’s Placebo Controlled Relapse Prevention TrialTime to Relapse Cumulative % Relapse Treatment Month From Hogarty et al 1974

  5. 1970’s Placebo Controlled Relapse Prevention Trial • Placebo relapse rate significantly higher than active medication • 75 percent of relapses led to hospitalization • Placebo relapse rate consistent over time • Approximately 3% per month • Psychosocial treatment may reduce relapse in second year in medicated patients Hogarty et al 1974

  6. 1990’s Placebo Controlled Relapse Prevention Trial:Study Design • Schizophrenia diagnosis • Hospitalized stabilized patients • One year treatment period • Three doses of ziprasidone v PBO • Definition of “impending” relapse depended upon observation over three day period • Multi-center European • sponsored by Pfizer, Inc. Arato et al 2002

  7. 1990’s Placebo Controlled Relapse Prevention Trial • Placebo relapse rate significantly higher than active medication • In hospitalized patients risk of hospitalization is controlled • Medication - placebo differences increase over time Arato et al 2002

  8. Summary from Placebo Controlled Trials • Anti-psychotic medications are effective in delaying relapse • Relapse is not prevented by medication • All studies show relapse on medication albeit at reduced rates • Among patients who are stable on medication – placebo differences may be difficult to detect in the first weeks of placebo substitution

  9. Can Long-Term, Placebo-Controlled Studies be Designed to Prevent Undue Harm to Patients? • Prodromal signs and symptoms often precede relapse • Monitoring of early signs could allow early intervention before a full relapse occurs • Strategy has several names • Early intervention • Targeted treatment • Intermittent treatment

  10. A 1980s – 1990s Placebo Controlled Trial Using an Early Intervention StrategyStudy Design • Schizophrenia diagnoses • Community dwelling stabilized patients with families • 2 year treatment period – pts seen at least every two weeks • 3 X 2 design • Fluphenazine decanoate • Moderate dose • Low dose • Placebo • High v low intensity family intervention – education about prodromal signs in both groups • Early intervention with oral fluphenazine at prodromal signs • in ALL groups • Definition of relapse required 140 days of open label medication • Multi center US • sponsored by NIMH Schooler et al 1997

  11. A 1980s – 1990s Placebo Controlled Trial Using an Early Intervention StrategyTime to Relapse Cumulative Proportion in Treatment Months Schooler et al 1997

  12. A 1980s – 1990s Placebo Controlled Trial Using an Early Intervention Strategy • Early intervention condition looks like placebo • Relapse rates were lowest in moderate dose, intermediate in low dose and highest in early intervention • Rehospitalization • Moderate and low dose – 24% • Early intervention – 48% Schooler et al. 1997

  13. Conclusions Regarding Early Intervention • Early intervention does not effectively prevent relapse • Relapse rates look like those with placebo • Use of “impending” relapse as an endpoint does not prevent rehospitalization of patients who are not receiving anti-psychotic medication • Withdrawal of medication in stable patients may have substantial socioeconomic effects even if patients are monitored closely

  14. Summary • Placebo produces increased relapse compared to active medication in long-term trials • 75% rehospitalization in community sample • 48% rehospitalization with early intervention • Early intervention strategies for rescue of placebo treated patients do not prevent relapse or rehospitalization • Use of placebo leads to unacceptable risks

More Related